Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma

Published:2018-02 Issue:1 Volume:28 Page:44-51
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Chesney Jason,Awasthi Sanjay,Curti Brendan,Hutchins Laura,Linette Gerald,Triozzi Pierre,Tan Marcus C.B.,Brown Russell E.,Nemunaitis John,Whitman Eric,Windham Christopher,Lutzky Jose,Downey Gerald F.,Batty Nicolas,Amatruda Thomas

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference21 articles.

1. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016

2. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010

3. The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer;Ries;Cancer,2000

4. Final version of 2009 AJCC melanoma staging and classification;Balch;J Clin Oncol,2009

5. Systemic treatments for advanced cutaneous melanoma;Anderson;Oncology (Williston Park),1995

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoantigen-specific T cell help outperforms non-specific help in multi-antigen DNA vaccination against cancer;Molecular Therapy: Oncology;2024-09

2. Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy;Journal of Translational Medicine;2023-07-25

3. Development and application of oncolytic viruses as the nemesis of tumor cells;Frontiers in Microbiology;2023-06-12

4. Vaccinating against cancer: getting to prime time;Journal for ImmunoTherapy of Cancer;2023-06

5. Oncolytic Virus‐Driven Biotherapies from Bench to Bedside;Small;2023-03-06